Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.
American Journal of Psychiatry June 1, 2026 Jason M Tucciarone, Igor D. Bandeira, Christine Blasey et al. 5 citations
Ketamine rapidly reduces suicidal ideation in major depressive disorder (MDD), but its effects are transient. Preclinical and clinical studies suggest that ketamine's antidepressant and antisuicidal effects may be partly mediated by mu-opioid receptor (MOR) modulation. The authors investigated the efficacy and safety of low-dose sublingual buprenorphine, a partial MOR agonist, as a follow-on...
DOI: 10.1176/appi.ajp.20250840 (opens in new tab)
Full text (opens in new tab)
Major depressive disorder
Bipolar disorder
Buprenorphine
Ketamine/esketamine
+1